ALA flies on a " vector anns " for a trial about 18-24 months away.
CHM already got its one for a trial commenecing soon, why aren't we flying too?
09 March 2023
“Vector supply continues to significantly challenge the cell therapy industry with current
backlogs of more than a year to access vector manufacturing,” said Chimeric CEO and Managing
Director Jennifer Chow. “Securing vector supply for the CHM 2101 Phase 1A clinical trial marks
a significant milestone for advancing CHM 2101 towards the clinic and patients that need novel
therapies to treat advanced gastrointestinal and neuroendocrine tumours.”
GLTA
Ann: Completion of Viral Vector Manufacturing for Phase 1 trial, page-8
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(25.0%) |
Mkt cap ! $6.045M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.3¢ | $22.28K | 6.311M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 78 | 84735861 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 86304338 | 23 |
View Market Depth
| Last trade - 14.27pm 25/07/2025 (20 minute delay) ? |
| CHM (ASX) Chart |